Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mizue Ichinose, Itaru Miura, Sho Horikoshi, Shinnosuke Yamamoto, Keiko Kanno-Nozaki, Kenya Watanabe & Hirooki Yabe. (2021) Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder. Neuropsychiatric Disease and Treatment 17, pages 1047-1053.
Read now
Read now
Suzan Kudlek Mikulic, Alma Mihaljevic-Peles, Marina Sagud, Maja Bajs Janovic, Lana Ganoci, Jasmina Grubisin, Martina Kuzman Rojnic, Bjanka Vuksan Cusa, Zoran Bradaš & Nada Božina. (2017) Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study. Nordic Journal of Psychiatry 71:7, pages 513-520.
Read now
Read now
Hikaru Hori, Reiji Yoshimura, Asuka Katsuki, Kiyokazu Atake, Ryohei Igata, Yuki Konishi & Jun Nakamura. (2017) Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy. The World Journal of Biological Psychiatry 18:5, pages 401-408.
Read now
Read now
Kenji Takeyoshi, Masatake Kurita, Satoshi Nishino, Mika Teranishi, Yukio Numata, Tadahiro Sato & Yoshiro Okubo. (2016) Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function. Neuropsychiatric Disease and Treatment 12, pages 641-649.
Read now
Read now
Articles from other publishers (27)
Albert Martínez-Pinteño, Gisela Mezquida, Miquel Bioque, Jose M López-Ilundain, Álvaro Andreu-Bernabeu, Iñaki Zorrilla, Anna Mané, Roberto Rodríguez-Jiménez, Iluminada Corripio, Salvador Sarró, Ángela Ibáñez, Judith Usall, Olga Rivero, Patricia Gassó, Juan Carlos Leza, Manuel J Cuesta, Mara Parellada, Ana González-Pinto, Esther Berrocoso, Sergi Mas, Miguel Bernardo, S Amoretti, C Morén, E Urbiola, J González-Peñas, A Roldán, A Catalán, I González-Ortega, A Toll, T Legido, L Sanchez-Pastor, M Dompablo, E Pomarol-Clotet, Landín-Romero R, A Butjosa, E Rubio, Lorente-OmeñacaR, M Ribeiro, I López-Torres, L León-Quismondo, J Nácher, F Contretas, A Lobo, M Gutiérrez-Fraile & PA Sáiz. (2022) The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study. European Neuropsychopharmacology 57, pages 105-117.
Crossref
Crossref
Xiaoqian Fu, Yansong Liu, Ancha Baranova & Fuquan Zhang. (2022) Deregulatory miRNA-BDNF Network Inferred from Dynamic Expression Changes in Schizophrenia. Brain Sciences 12:2, pages 167.
Crossref
Crossref
. (2021) Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”. Neuropsychopharmacology Reports 41:3, pages 266-324.
Crossref
Crossref
Masayuki Takase, Hisoshi Kimura, Nobuhisa Kanahara, Yusuke Nakata & Masaomi Iyo. (2020) Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis. Journal of Psychopharmacology 34:5, pages 540-547.
Crossref
Crossref
Samantha Alvarez-Herrera, Raúl Escamilla, Oscar Medina-Contreras, Ricardo Saracco, Yvonne Flores, Gabriela Hurtado-Alvarado, José Luis Maldonado-García, Enrique Becerril-Villanueva, Gilberto Pérez-Sánchez & Lenin Pavón. (2020) Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics. Frontiers in Endocrinology 11.
Crossref
Crossref
Hikaru Hori, Reiji Yoshimura, Asuka Katsuki & Kiyokazu Atake. (2020) Plasma levels of 3-methoxy-4-hydroxyphenylglycol levels, number of hospitalization and cognitive function predicts the cognitive effect of atypical antipsychotic monotherapy in patients with acute schizophrenia. International Clinical Psychopharmacology 35:2, pages 89-97.
Crossref
Crossref
Tomasz Pawełczyk, Marta Grancow-Grabka, Elżbieta Trafalska, Janusz Szemraj, Natalia Żurner & Agnieszka Pawełczyk. (2019) An increase in plasma brain derived neurotrophic factor levels is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the OFFER randomized clinical trial. Psychopharmacology 236:9, pages 2811-2822.
Crossref
Crossref
Itaru Miura, Yasuto Kunii, Mizuki Hino, Hiroshi Hoshino, Junya Matsumoto, Keiko Kanno-Nozaki, Sho Horikoshi, Haruka Kaneko, Miki Bundo, Kazuya Iwamoto & Hirooki Yabe. (2018) DNA methylation of ANKK1 and response to aripiprazole in patients with acute schizophrenia: A preliminary study. Journal of Psychiatric Research 100, pages 84-87.
Crossref
Crossref
Anilkumar Pillai, Nina R. Schooler, Diya Peter, Stephen W. Looney, Donald C. Goff, Alexander Kopelowicz, John Lauriello, Theo Manschreck, Alan Mendelowitz, Del D. Miller, Joanne B. Severe, Daniel R. Wilson, Donna Ames, Juan Bustillo, John M. Kane & Peter F. Buckley. (2018) Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?. Schizophrenia Research 193, pages 263-268.
Crossref
Crossref
Hikaru Hori, Reiji Yoshimura, Asuka Katsuki, Kiyokazu Atake, Ryohei Igata, Yuki Konishi, Hiroki Beppu & Hirotaka Tominaga. (2017) Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia. International Journal of Molecular Sciences 18:3, pages 568.
Crossref
Crossref
Reiji Yoshimura, Hikaru Hori, Asuka Katsuki, Kiyokazu Atake & Jun Nakamura. (2016) Serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-methoxy-4-hydroxyphenylglycol levels in chronic schizophrenia. Annals of General Psychiatry 15:1.
Crossref
Crossref
Kenya Watanabe, Itaru Miura, Keiko Kanno-Nozaki, Sho Horikoshi, Hirobumi Mashiko, Shin-Ichi Niwa & Hirooki Yabe. (2015) Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia. Psychiatry Research 230:2, pages 419-423.
Crossref
Crossref
B S Fernandes, J Steiner, M Berk, M L Molendijk, A Gonzalez-Pinto, C W Turck, P Nardin & C-A Gonçalves. (2014) Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Molecular Psychiatry 20:9, pages 1108-1119.
Crossref
Crossref
M. Martinez-Cengotitabengoa, K.S. MacDowell, S. Alberich, F.J. Diaz, B. Garcia-Bueno, R. Rodriguez-Jimenez, M. Bioque, E. Berrocoso, M. Parellada, A. Lobo, P.A. Saiz, C. Matute, M. Bernardo, A. Gonzalez-Pinto & J.C. Leza. (2015) BDNF and NGF Signalling in Early Phases of Psychosis: Relationship With Inflammation and Response to Antipsychotics After 1 Year. Schizophrenia Bulletin, pages sbv078.
Crossref
Crossref
Nora W.A. van de Kerkhof, Durk Fekkes, Frank M.M.A. van der Heijden, Jos I.M. Egger & Willem M.A. Verhoeven. (2015) Relationship between Plasma Homovanillic Acid and Outcome in Patients with Psychosis Spectrum Disorders. Neuropsychobiology 71:4, pages 212-217.
Crossref
Crossref
Trevor Archer, Serafino Ricci, Danilo Garcia & Max Rapp Ricciardi. (2014) Neurodegenerative Aspects in Vulnerability to Schizophrenia Spectrum Disorders. Neurotoxicity Research 26:4, pages 400-413.
Crossref
Crossref
Błażej Misiak, Dorota Frydecka, Marcin Zawadzki, Maja Krefft & Andrzej Kiejna. (2014) Refining and integrating schizophrenia pathophysiology – Relevance of the allostatic load concept. Neuroscience & Biobehavioral Reviews 45, pages 183-201.
Crossref
Crossref
Trevor Archer, Ulla Karilampi, Serafino Ricci & Max Rapp-Ricciardi. 2014. Handbook of Neurotoxicity. Handbook of Neurotoxicity
2181
2205
.
Hikaru Hori, Reiji Yoshimura, Asuka Katsuki, Atsuko-Ikenouchi Sugita, Kiyokazu Atake & Jun Nakamura. (2013) Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. Journal of Psychiatric Research 47:12, pages 1843-1848.
Crossref
Crossref
Chirayu D. Pandya, Ammar Kutiyanawalla & Anilkumar Pillai. (2013) BDNF–TrkB signaling and neuroprotection in schizophrenia. Asian Journal of Psychiatry 6:1, pages 22-28.
Crossref
Crossref
Pao-Yen Lin. (2012) Increase in Brain-derived Neurotrophic Factor in Patients with Schizophrenia Treated with Olanzapine: A Systemic Review and Meta-analysis. Journal of Experimental & Clinical Medicine 4:2, pages 119-124.
Crossref
Crossref
Gabriela Favalli, Jennifer Li, Paulo Belmonte-de-Abreu, Albert H.C. Wong & Zafiris Jeffrey Daskalakis. (2012) The role of BDNF in the pathophysiology and treatment of schizophrenia. Journal of Psychiatric Research 46:1, pages 1-11.
Crossref
Crossref
Reiji Yoshimura, Hikaru Hori, Atsuko Ikenouchi-Sugita, Wakako Umene-Nakano, Asuka Katsuki, Kenji Hayashi, Kiyokazu Atake, Masaru Tomita & Jun Nakamura. (2012) Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Human Psychopharmacology: Clinical and Experimental 27:1, pages 33-38.
Crossref
Crossref
Chien-Chih Chen & Tiao-Lai Huang. (2011) Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry Research 189:3, pages 327-330.
Crossref
Crossref
Yan Qiu Yang, Shilong Sun, Ya Qin Yu, Wen Jun Li, Xuan Zhang, Mei Hong Xiu, Da Chun Chen, Fu De Yang, Haibo Liu, Cunbo Li, Thomas R. Kosten & Xiang Yang Zhang. (2011) Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia. Neuroscience Letters 502:1, pages 37-40.
Crossref
Crossref
S. Porcelli, A. Drago, C. Fabbri & A. Serretti. (2011) Mechanisms of antidepressant action: An integrated dopaminergic perspective. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:7, pages 1532-1543.
Crossref
Crossref
Fabiano R. Agostinho, Gislaine Z. Réus, Roberto B. Stringari, Karine F. Ribeiro, Bianca Pfaffenseller, Laura Stertz, Bruna S. Panizzutti, Flávio Kapczinski & João Quevedo. (2011) Olanzapine plus fluoxetine treatment increases Nt-3 protein levels in the rat prefrontal cortex. Neuroscience Letters 497:2, pages 99-103.
Crossref
Crossref